secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2026-08-06T12:05:35+00:00
Accession:  0001104659-26-091671
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q2 net loss $57.3M; completes sevasemten sale to Servier for up to $2.65B
--------------------------------------------------------------------------------

- Net loss $57.3M ($0.53/share) vs $36.1M ($0.34) in Q2 2025; R&D $47.5M, G&A $14.4M.
- Completed sale of sevasemten and muscular dystrophy business to Servier for $1.55B upfront + up to $1.1B milestones (closed July 2026).
- Cash $460.7M at June 30; pro forma $2.01B after sale proceeds (pre-tax/transaction costs).
- Positive top-line Phase 2 CIRRUS-HCM data for EDG-7500 in HCM; Phase 3 expected Q4 2026.
- EDG-15400 Phase 1 completed; Phase 2 in HFpEF expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/0001104659-26-091671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926091671/tm2621653d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer